



Covalent Binding – From 20th Century Liability to 21st Century Targeted Therapies

Greg Slatter, PhD

**Clinical Pharmacology
Kartos Therapeutics Inc.
Bellevue, WA**

**DVDMDG - Rozman Symposium
Philadelphia, June 11 2019**

From 20th Century Liability to 21st Century Targeted Therapies

Covalent Binding as a Liability

- Acetaminophen and NAPQI
- Reversibility & Selectivity
- Carbamoylating Metabolites
- Mitigating Risk Related to Covalent Binding

Targeted Covalent Agents

- Disulfide
- Covalent Binding Kinetics
- DPPIV Inhibitor
- Maximizing Benefit:risk
- BTK Inhibitor
- Conclusion

Reading List

Acetaminophen/NAPQI

Mitchell JR et al., J Pharmacol Exp Ther. 1973 187 211-17
Dahlin DC et al., Proc Natl Acad Sci USA 1984 81(5):1327-31
Andersson DA et al., Nature Commun. 2011 2:551-11

Carbamoylating Metabolites

Slatter JG et al., Chem Res Toxicol. 1993 6 335-40
Pearson PG et al., Biochem Biophys Res Commun. 1990 166 :245-50.
Baillie TA, Slatter JG. Accounts Chem Res. 1991 24: 264–270
Coghlan A. New Scientist 14 Dec 1991

Mitigating Risk

Obach RS et al., Chem Res Toxicol. 2008 21:1814-22
Johnson DS et al., Future Med Chem. 2010 2 949-64
Nakayama S et al., Drug Metab Disp. 2009 37 1970-77

Disulfide

Subramanian R et al., Clinical Pharmacokinetics 2017 56 179-92

Covalent Binding Kinetics

Schwartz PA et al., Proc Natl Acad Sci USA 2014 111 173-8
Barf T, Kaptein A. J Med Chem. 2012 26 55:6243-62

DPPIV Inhibitor

Greene RJ et al., Xenobiotica. 2011 41(11):945-57
Hughes TE et al., Biochemistry. 1999 7;38:11597-603
Fuchs H et al., J Pharm Pharmacol. 2009 61:55-62
Retlich S et al., J Clin Pharmacol. 2010 50: 873-85
Schnapp G et al., J Med Chem. 2016 59: 7466-77

Maximizing Benefit:Risk

Baillie T. Angw Chem. 2017 55 13408-21
Barf T, Kaptein A. J Med Chem. 2012 26 55:6243-62.

BTK Inhibitor

Byrd JC et al., N Engl J Med. 2016 28;374:323-32
Wang M et al., Lancet 2018 Feb 17;391(10121):659-667
Barf T et al., J Pharmacol Exp Ther. 2017;363:240-252
Podoll T et al., Drug Metab Disp. 2019 47 145-154